Idorsia Ltd (SWX:IDIA)
4.014
0.00 (0.00%)
Nov 12, 2026, 12:07 PM CET
Idorsia Revenue
Idorsia had revenue of 61.92M CHF in the quarter ending September 30, 2026, with 49.26% growth. This brings the company's total for the last twelve months to 220.15M, down -5.32% year-over-year. In the year 2025, Idorsia had annual revenue of 220.58M with 96.06% growth. That makes Idorsia the 15,465th largest company in the world by revenue and 149th in Switzerland.
Revenue (ttm)
220.15M
Revenue Growth
-5.32%
P/S Ratio
4.92
Revenue / Employee
482.78K
Employees
487
Market Cap
1.08B
Revenue by Geography
- Switzerland 90.74M 41.1%
- France 67.43M 30.6%
- EUCAN 35.42M 16.1%
- United States 26.99M 12.2%
Fiscal year ended Dec 31, 2025 See the full Idorsia breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.58M | 108.08M | 96.06% |
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 708.53M |
| Basilea Pharmaceutica AG | 247.42M |
| Santhera Pharmaceuticals Holding AG | 101.50M |
| Newron Pharmaceuticals | 9.62M |
| BioVersys AG | 4.62M |
| MindMaze Therapeutics Holding | 1.20M |
| Molecular Partners AG | 681.00K |
| Xlife Sciences AG | 397.23K |
Idorsia News
- 2 days ago - Idorsia Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 7 days ago - Idorsia Transcript: Investor update - Transcripts
- 7 days ago - Idorsia Press release: Investor update - Filings
- 7 days ago - Idorsia Slides: Investor update - Filings
- 13 days ago - Idorsia Q3 Loss Narrows As Revenue Rises; Proposes CHF120 Mln Hypertension Drug Partnership - Nasdaq
- 14 days ago - Idorsia Earnings release: Q3 2026 - Filings
- 14 days ago - Idorsia Quarterly report: Q3 2026 - Filings
- 15 days ago - Idorsia Slides: Investor presentation - Filings